Trends in total and out-of-pocket payments for insulin among privately insured U.S. adults with diabetes from 2005 to 2018
| Autor: | Giuseppina Imperatore, Stephen R. Benoit, Yiling J. Cheng, Hui Shao, Ping Zhang, Shuang Yang, Edward W. Gregg, Michael Laxy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Advanced and Specialized Nursing
Type 1 diabetes education.field_of_study medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment media_common.quotation_subject Population Type 2 diabetes medicine.disease Payment Diabetes mellitus Family medicine Internal Medicine medicine Medicare Part D Medical prescription education business health care economics and organizations media_common |
| Zdroj: | Diabetes Care 44, e1-e3 (2021) |
| Popis: | More than 30 million people in the U.S. have diabetes, and approximately 7.4 million (30% of those with diabetes) regularly use one or more insulin formulations. For those who rely on it, i.e., all patients with type 1 diabetes and many patients with type 2 diabetes, insulin is a lifesaving medication. Between 2007 and 2016, the average annual total Medicare Part D payment on insulin per person increased by 358%, which resulted in an 81% increase for the out-of-pocket (OOP) payment (1). The consequences of unaffordability for insulin can be severe and costly. High OOP payments may force individuals to choose between purchasing their medication and paying for other necessities. To date, there are limited data on how total insulin payment and the corresponding OOP payment changed in the commercially insured population within the same period. The objective of this study is to delineate total and patients’ OOP payment trends for insulin among privately insured U.S. adults. We analyzed the IBM MarketScan Commercial Claims and Encounters (CCE) database for the period 2005 to 2018. The CCE contains de-identified patient claims data across the continuum of care (e.g., inpatient, outpatient, pharmacy) from large employers and health plans in the U.S. that provide private insurance coverage for their employees, dependents, and retirees. The primary analytical unit is the insulin prescription of adult individuals with diabetes covered by fee-for-service plans. We defined … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|